GSK vs MRBK · P/E 13, $103.31B cap vs P/E 11, rev $3.4M
GlaxoSmithKline PLC ADR (GSK) versus Meridian Bank (MRBK) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Meridian Bank (MRBK) is a banks - regional company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported MRBK revenue for 2026-06-30 was $3.4M. Net income was $7.8M. Revenue was up 98.7% from 2026-03-31 to 2026-06-30. MRBK currently screens at market cap $236.3M and trailing P/E 10.7.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. MRBK currently screens at market cap $236.3M and trailing P/E 10.7.
Not investment advice. Open the GSK and MRBK stock pages for the full models.
Not investment advice.